NICE Technology Appraisal 176

Cetuximab for the first-line treatment of metastatic colorectal cancer

Summary:
  • Cetuximab in combination with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan is only recommended as a possible treatment for metastatic colorectal cancer if patients meet the specified NICE criteria
  • Treatment with cetuximab should stop after 16 weeks and the person should be assessed to see if they can have surgery to remove the metastases in their liver.
 
Web address: www.nice.org.uk/Guidance/TA176

NICE Technology Appraisal 177

Alitretinoin for the treatment of severe chronic hand eczema

Summary:
  • Alitretinoin is recommended as a possible treatment for people with severe chronic hand eczema if:
    • their eczema has not improved with the use of potent topical corticosteroids and
    • standard assessments show that their eczema is severe and is affecting their quality of life
  • Treatment with alitretinoin should be stopped:
    • as soon as eczema has clearly improved or
    • if the eczema remains severe after 12 weeks or
    • if the eczema has not clearly improved after 24 weeks.
 
Web address: www.nice.org.uk/Guidance/TA177

NICE Technology Appraisal 178

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

Summary:
  • Bevacizumab, sorafenib, and temsirolimus are not recommended as first-line treatments in patients with advanced and/or metastatic renal cell carcinoma
  • Sorafenib and sunitinib are not recommended as second-line treatments in patients with advanced and/or metastatic renal cell carcinoma.
 
Web address: www.nice.org.uk/Guidance/TA178